Background: Colorectal cancer is the third most common type of cancer with the fourth-highest mortality rate in Indonesia. Early diagnosis and prompt treatment are the keys to effective management. Colorectal cancer also causes an increased risk of hypercoagulation, one of which can be evaluated through the D-Dimer value. Treatment with systemic chemotherapy that targets angiogenesis via the VEGF pathway is often unsuccessful, despite the low evaluation of tumor biomarkers (CEA) at the end of therapy. Given the possibility of a colorectal cancer population with negative CEA, other tumor markers are needed that can predict the clinical outcome of colorectal cancer patients that are independent of the effect of VEGF. The prognostic marker that is believed to have this ability is D-dimer which can be detected in the serum of colorectal cancer patients.

Aims: To evaluate prognostic value of D-dimer in colorectal cancer.

Methods: This study was conducted at the Medical Oncology Haematology Polyclinic and the inpatient ward of the Internal Medicine Division of RSMH Palembang from November 2020 to March 2021. Data processing and analysis using SPSS version 26.0 for Windows.

Results: From 70 subjects were followed during the study period and had received six times complete and timely systemic chemotherapy. After assessing the clinical outcome in the form of response to chemotherapy treatment, the subjects were divided into a non-responder group of 52 people (74.3%) and a group of 18 respondents (25.7%). By using the Chi-Square test, the p-value = 0.017 (multivariate analysis), OR 0.017 (95% CI 0.02–0.67).

Conclusion(s): D-dimer has good prognostic value in predicting colorectal cancer treatment response

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/prechemotherapy-d-dimer-levels-as-predictors-of-response-treatment-in-colorectal-cancer/